Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05786040 · ClinicalTrials.gov registry record · Phase 2

Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder

A Phase 2 study of Polymorphic Post-Transplant Lymphoproliferative Disorder and Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder, sponsored by Timothy Voorhees.

Recruiting
Registry status
Phase 2
Development phase
28
Enrollment target
3
Study locations

NCT05786040: Recruiting Phase 2 study of Polymorphic Post-Transplant Lymphoproliferative Disorder and Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder, sponsored by Timothy Voorhees.

NCT05786040 is a Phase 2 study of Polymorphic Post-Transplant Lymphoproliferative Disorder and Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder that is actively recruiting participants, run by Timothy Voorhees. The registered enrollment target is 28 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (79% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05786040, a Phase 2 study of Polymorphic Post-Transplant Lymphoproliferative Disorder and Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder, is actively recruiting participants, sponsored by Timothy Voorhees.

RECRUITING
Registry status
Phase 2
Development phase
28 participants
Enrollment target
3
Study locations

Study Summary

This phase II trial tests how well tafasitamab and rituximab work for front-line treatment of patients with post-transplant lymphoproliferative disorder. Post-transplant lymphoproliferative disorder (PTLD) is the name for types of lymphoma that sometimes develop in people who have had a transplant. It can affect people who are taking medicines to suppress their immune system. Tafasitamab injection is in a class of medications called monoclonal antibodies. It works by helping the body to slow or stop the growth of cancer cells. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Giving the combination of tafasitamab and rituximab may work better in treating patients with post-transplant lymphoproliferative disorder.

Primary Outcome

Assessed using Lugano criteria. Will be calculated as the number of patients who achieve CR divided by the number of evaluable patients, and presented with the 95% binomial confidence interval.

Conditions Studied

Polymorphic Post-Transplant Lymphoproliferative Disorder Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder

Interventions

  • PROCEDURE Biospecimen Collection
  • PROCEDURE Computed Tomography
  • PROCEDURE Biopsy
  • PROCEDURE Positron Emission Tomography
  • BIOLOGICAL Rituximab

Study Locations (3)

New Jersey

  • Rutgers Cancer Institute of New Jersey - New Brunswick

North Carolina

  • University of North Carolina-Hillsborough Campus - Hillsborough

Ohio

  • Ohio State University Comprehensive Cancer Center - Columbus

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2023-03-23
Est. Completion 2027-12-31
Phase Phase 2
Timothy Voorhees

3 total trials

What NCT05786040 shows while recruiting

NCT05786040 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (79% lower).

The record links to 2 conditions, with Polymorphic Post-Transplant Lymphoproliferative Disorder appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.

NCT05786040 reports a single indexed study location in New Jersey, North Carolina, Ohio.

Frequently Asked Questions

What is clinical trial NCT05786040 about?

NCT05786040 is a clinical study titled "Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder". This phase II trial tests how well tafasitamab and rituximab work for front-line treatment of patients with post-transplant lymphoproliferative disorder. Post-transplant lymphoproliferative disorder (PTLD) is the name for types of lymphoma that sometimes develop in people who have had a transplant. ...

What is the current status of trial NCT05786040?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2023-03-23. Estimated completion is 2027-12-31.

What conditions does trial NCT05786040 study?

This clinical trial studies the following conditions: Polymorphic Post-Transplant Lymphoproliferative Disorder, Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder.

What interventions are being tested in trial NCT05786040?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Biopsy (PROCEDURE), Positron Emission Tomography (PROCEDURE), Rituximab (BIOLOGICAL).

Who is sponsoring clinical trial NCT05786040?

This trial is sponsored by Timothy Voorhees, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05786040 being conducted?

This trial has 3 study locations across New Jersey, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Polymorphic Post-Transplant Lymphoproliferative Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05786040's enrollment target sits among peer trials

28 1677th of 2000 higher than 304 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03471117 · 28 participants · Phase 4

    Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients

  • NCT03523975 · 28 participants · Phase 1

    Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

  • NCT03608631 · 28 participants · Phase 1

    iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation

  • NCT03810651 · 28 participants · Early Phase 1

    Pencil Beam Scanning in Patients With Renal Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05786040

Source: ClinicalTrials.gov NCT05786040, the US trial registry maintained by the National Library of Medicine. NCT05786040 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.